Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|April 4, 2018
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA studyBenedicte Deau, Sandy Amorim, Aurore Perrot, et al.
Leukemia & Lymphoma|February 17, 2016
Does bendamustine impact the mobilization of peripheral blood stem cells? A multicenter retrospective study of 23 casesAnne-Claire Gac, Nabih Azar, Etienne Daguindau, et al.
The Lancet. Haematology|April 12, 2016
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 studySandy Amorim, Anastasios Stathis, Mary Gleeson, et al.
The Lancet. Haematology|December 22, 2015
Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 studyJehan Dupuis, Franck Morschhauser, Hervé Ghesquières, et al.
Annals of Hematology|May 22, 2019
BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)Jérôme Cornillon, Elisabeth Daguenet, Jacques-Olivier Bay, et al.
Cancer Immunology, Immunotherapy : CII|September 9, 2019
Presence of T cells directed against CD20-derived peptides in healthy individuals and lymphoma patientsBenoit Milcent, Nathalie Josseaume, Quentin Riller, et al.
Blood Advances|December 8, 2022
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA groupRaphaelle Aubrais, Krimo Bouabdallah, Loic Chartier, et al.
Annals of Hematology|January 26, 2021
Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohortFlorian Bouclet, Anne Calleja, Marie-Sarah Dilhuydy, et al.
Haematologica|May 28, 2026
Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa studyJulien Lazarovici, Sandy Amorim, Krimo Bouabdallah, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Pageof 3